Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder – An 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients-Reference-Cited by-同舟云学术

Kava-Kava extract LI 150 is as effective as Opipramol and Buspirone in Generalised Anxiety Disorder – An 8-week randomized, double-blind multi-centre clinical trial in 129 out-patients

Published:2003-01 Issue: Volume:10 Page:38-49
ISSN:0944-7113
Container-title:Phytomedicine
language:en
Short-container-title:Phytomedicine

Author:

Boerner R.J.,Sommer H.,Berger W.,Kuhn U.,Schmidt U.,Mannel M.

Publisher

Elsevier BV

Subject

Complementary and alternative medicine,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine

Reference43 articles.

1. Venlafaxine extended release (ER) in the treatment of generalized anxiety disorder. Twenty-four-week placebo-controlled dose-ranging study;Allgulander;Br J Psychiatry,2001

2. Buspirone HCl;Anonymous,1998

3. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia;Boerner;Phytother Res,2001

4. Kava kava in the treatment of generalized anxiety disorder, simple phobia and specific social phobia;Boerner;Phytother Res,2001

5. RJ Boerner (2002a) Angststörungen. In: Neuro—Psychopharmaka, vol. 3, 2nd ed. (eds Riederer P et. al.). Springer, Wien (in press)

Cited by 114 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AB-free kava enhances resilience against the adverse health effects of tobacco smoke in mice;2024-06-29

2. Kava‐induced dermatitis: A detailed histopathological analysis;Australasian Journal of Dermatology;2024-05-20

3. The efficacy, safety, and adverse events of azapirones in anxiety disorders: A systematic review and meta-analysis of randomized controlled trials;European Neuropsychopharmacology;2023-11

4. Herbal Approaches in the Management of Mental Depression;CNS & Neurological Disorders - Drug Targets;2023-01

5. Nip it in the Bud: Botanicals for Anxiety — a Practical Prescriber’s Guide;Current Psychiatry Reports;2022-09-01